Open for Business: Early Phase Clinical Drug Development dur...
The global COVID-19 pandemic has altered the mechanics of nearly every industry. For early phase cli...
Blog
COVID-19, Kawasaki and the Cytokine Storm
by Sabina Paglialunga, PhD - Director, Scientific Affairs, Celerion SARS-CoV-2 symptoms include feve...
Blog
Capturing the Cytokine Storm: Using Biomarkers in COVID-19 T...
By Sumit Kar, Lead Scientist – Biomarkers, Celerion Cytokine biomarkers are released in the body aft...
Blog
Pharmabiotics – Spreading Culture to Therapeutic Drugs
In the therapeutic toolbox, there is a multitude of drug categories. For decades, small molecules ha...
Blog
COVID-19 Vaccines in Development
COVID-19 Vaccines in Development COVID-19 is a respiratory illness caused by a novel coronavirus. Ac...
Blog
Backing the Biosimilar Boon
Biological therapies such as peptides, enzymes and antibodies have changed the face of medicine, pro...
Blog
Innovations in COPD – A Breath of Fresh Air
Chronic obstructive pulmonary disease (COPD) describes a cluster of diseases linked to breathing pro...
Blog
Entering the NASH Race: Tips for Early Clinical Development
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that affects over 17 million American...
Blog
The Next Frontier of Pharmacology: Micro Drug Delivery
Injectable medication can be burdensome for the patient, causing pain and discomfort, and can contri...